imunon.com (IMNN) Long-Term Debt to Capital Ratio

Imunon, Inc. (IMNN) is developing DNA cancer vaccines while optimizing expenses to drive future cash flow growth. Revenues are based on the licensing of the Theraiva platform and sales of ovarian cancer therapies. Success depends on clinical trial results amid stable liquidity levels. The long-term debt-to-equity dynamics confirm these data, where the current mark is 1.34.

Developing innovative DNA vaccines requires significant capital expenditures for clinical trials. The current long-term debt-to-equity ratio for Imunon, Inc. (IMNN) illustrates the extent to which the financing of these developments relies on borrowed funds. This ratio compares liabilities with a maturity of over one year against the company's equity. While a low value minimizes default risk, excessive conservatism may slow the pace of expansion. It is critical for investors to find a balance between financial stability and aggressive growth.